1. The insect cell expression platform
An international leading insect cell expression and large-scale production platform in China, and the fourth production enterprise in the world following Sanofi, GSK, and Novavax. It boasts a large production scale and leads in international product quality. Two production bases have been established in Chengdu Tianfu International Bio-town and Guangzhou Development Zone, with a total of three large-scale commercial insect cell production lines (1 x3000L and 2 x 5000L), an annual production capacity exceeding 100 million doses. The GMP production workshops of WestVac Biopharma have obtained certifications from authoritative institutions in China and abroad. Three Recombinant COVID-19 protein vaccines and their variant strain iterative productsproduced on this platform have been approved for emergency use. Utilizing the insect cell platform, the company is actively promoting the industrializationof Recombinant trivalent influenza vaccines, COVID-flu combination vaccine, and other products.

2. The mRNA vaccine platform
The mRNA vaccine platform has broken through the patent barriers of mRNA delivery vehicles and sequence design, with a completely new design that has been granted international patent rights. Two products, including an EBV tumor vaccine, have received IND approval from the US FDA.

3. The new adjuvant 
The new adjuvant, with a COVID-19 vaccine using an MF59-like oil-in-water emulsion adjuvant, has been approved for emergency use in China. It is the first new type of adjuvant approved in China, apart from aluminum adjuvants, and several other new adjuvants are under development.

4. The tumor and immunotherapy platform
Built for various immune pathways and mechanisms of action, including in situ vaccines and intranasal vaccines, developing a variety of cancer vaccines/immunotherapy products.

5. The bacterial vaccine platform 
The bacterial vaccine platform uses a unique mechanism of action with inactivated whole bacteria, which has proven safety, effective immunogenicity, and high protective efficiency.

On these five major technology platforms, there is a development pipeline of more than 20 products, including COVID-19 vaccines and their iterative products (Recombinant COVID-19 trivalent XBB vaccine and Recombinant COVID-19 monovalent XBB vaccine), Recombinant trivalent influenza vaccine, Recombinant COVID-flu combination vaccine, Intranasal Respiratory Syncytial Virus (RSV) vaccine, Acne vaccine, Bacterial vaccine, Anti-fibrotic vaccine, and new therapeutic cancer vaccines, among others.